Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?

Virulence

Volumn 8, Issue 1, 2017, Pages 66-73

  Del Bono, Valerio ^a   Giacobbe, Daniele Roberto ^a   Marchese, Anna ^a   Parisini, Andrea ^b   Fucile, Carmen ^c   Coppo, Erika ^a   Marini, Valeria ^c   Arena, Antonio ^a   Molin, Alexandre ^a   Martelli, Antonietta ^c   Gratarola, Angelo ^a   Viscoli, Claudio ^a   Pelosi, Paolo ^a,c   Mattioli, Francesca ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b Ospedale Madonna del Popolo   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

bloodstream infections; carbapenemases; Klebsiella pneumoniae; KPC; meropenem MICs; PK PD; treatment

Indexed keywords

BILIRUBIN; COLISTIN; CREATININE; GENTAMICIN; MEROPENEM; SERUM ALBUMIN; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; MINOCYCLINE; THIENAMYCIN DERIVATIVE;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BLOODSTREAM INFECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG CLEARANCE RATIO; DRUG HALF LIFE; DRUG MEGADOSE; ELIMINATION RATE CONSTANT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KLEBSIELLA PNEUMONIAE INFECTION; LIMIT OF QUANTITATION; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; NOTE; PHARMACODYNAMICS; PROSPECTIVE STUDY; SEPTIC SHOCK; STRAIN IDENTIFICATION; TREATMENT FAILURE; VOLUME OF DISTRIBUTION; AGED; ANALOGS AND DERIVATIVES; BACTEREMIA; BIOSYNTHESIS; BLOOD; COMBINATION DRUG THERAPY; CRITICAL ILLNESS; DRUG POTENTIATION; ENZYMOLOGY; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; COLISTIN; CRITICAL ILLNESS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GENTAMICINS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; THIENAMYCINS;

EID: 84981541217     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.1080/21505594.2016.1213476     Document Type: Article

References (37)

1. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13:785-96; PMID:23969216; http://dx.doi.org/10.1016/S1473-3099(13)70190-7
2. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae:here is the storm! Trends Mol Med 2012; 18:263-72; PMID:22480775; http://dx.doi.org/10.1016/j.molmed.2012.03.003
3. Hirsch EB, Tam VH. Detection and treatment option for Klebsiella pneumoniae carbapenemases (KPCs):an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119-25; PMID:20378670; http://dx.doi.org/10.1093/jac/dkq108
4. Giacobbe DR, Del Bono V, Marchese A, Viscoli C. Early carbapenem-resistant Klebsiella pneumoniae bacteraemia:should we expand the screening? Clin Microbiol Infect 2014; 20:O1157-O1158; PMID:25366247; http://dx.doi.org/10.1111/1469-0691.12804
5. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae:epidemiology and prevention. Clin Infect Dis 2011; 53:60-7; PMID:21653305; http://dx.doi.org/10.1093/cid/cir202
6. Marchain D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, Endimiani A, Navon-Venezia S, Hothi J, Slim J, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011; 55:593-9; PMID:21115786; http://dx.doi.org/10.1128/AAC.01020-10
7. Alicino C, Giacobbe DR, Orsi A, Tassinari F, Trucchi C, Sarteschi G, Copello F, Del Bono V, Viscoli C, Icardi G. Trends in the incidence of carbapenem-resistant Klebsiella pneumoniae bloodstream infections:a 8-year retrospective study in a large teaching hospital in northern Italy. BMC Infect Dis 2015; 15:415; PMID:26464061; http://dx.doi.org/10.1186/s12879-015-1152-0
8. Giani T, Arena F, Vaggelli G, Conte V, Chiarelli A, Henrici De Angelis L, Fornaini R, Grazzini M, Niccolini F, Pecile P, et al. Large Nosocomial Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae Traced to Clonal Expansion of an mgrB Deletion Mutant. J Clin Microbiol 2015; 53:3341-4; PMID:26202124; http://dx.doi.org/10.1128/JCM.01017-15
9. Endimiani A, Hujer AM, Perez F, Bethel CR, Hujer KM, Kroeger J, Oethinger M, Paterson DL, Adams MD, Jacobs MR, et al. Characterization of blaKPC-containing Klebsiella Pneumoniae isolates detected in different institutions in the eastern USA. J Antimicrob Chemother 2009; 63:427-37; PMID:19155227; http://dx.doi.org/10.1093/jac/dkn547
10. Jiang Y, Wei Z, Wang Y, Hua X, Feng Y, Yu Y. Tracking a hospital outbreak of KPC-producing ST11 Klebsiella pneumoniae with whole genome sequencing. Clin Microbiol Infect 2015; 21:1001-7; PMID:26166545; http://dx.doi.org/10.1016/j.cmi.2015.07.001
11. Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, Valakis C, Maltezou HC. Group for the Study of KPC-producing Klebsiella pneumoniae infections in intensive care units. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece:a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014; 20:O117-O123; PMID:23992130; http://dx.doi.org/10.1111/1469-0691.12341
12. Corcione S, Rocchetti A, Argentero PA, Raso R, Zotti CM, De Rosa FG, Ghisetti V. A one-year survey of carbapenemase-producing Klebsiella pneumoniae in Italy:beyond the ICU. Clin Microbiol Infect 2015; 21:e11-e13; PMID:25682279; http://dx.doi.org/10.1016/j.cmi.2014.09.012
13. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae:superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108-13; PMID:22252816; http://dx.doi.org/10.1128/AAC.06268-11
14. Tumbarello M, Viscoli C, Viale P, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae:importance of combination therapy. Clin Infect Dis 2012; 55:943-50; PMID:22752516
15. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections:lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58:2322-8; PMID:24514083
16. Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, Bartoloni A, Losito AR, Corcione S, Bartoletti M, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae:results from a multicenter case-control-control study. Clin Microbiol Infect 2015; 21:1106.e1-8; PMID:26278669
17. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, et al. Infections caused by KPC-producing Klebsiella pneumoniae:differences in therapy and mortality in a multicentric study. J Antimicrob Chemother 2015; 70:2133-43; PMID:25900159
18. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae:(when) might we still consider treating with carbapenem? Clin Microbiol Infect 2011; 17:1135-41; PMID:21635663
19. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-6; PMID:12682500
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41; PMID:1244564
21. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a Once-Daily Aminoglycoside Program Administered to 2,184 Adult Patients. Antimicrob Agents Chemother 1995; 39:650-5; PMID:7793867
22. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430-6; PMID:19433570
23. Legrand T, Chhun S, Rey E, Blanchet B, Zahar JR, Lanternier F, Pons G, Jullien V. Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 875:551-6; PMID:18848512
24. International Conference on Harmonization (ICH). Harmonised tripartite guideline:Validation of analytical procedures:text and methodology Q2(R1) 6 November 1996. ICH Official web site. Available:http://www.ich.org. Accessed 2015May8
25. Shah VP, Midha KK, Dighe S. Conference report:analytical methods validation:bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci-US 1992; 81:309-12
26. Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam. J Antimicrob Chemother 2001; 48:259-67; PMID:114-81298
27. Marchese A., Coppo E, Barbieri R, Debbia E. Emergence of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains and spread of an isolate of sequence type 258 in the neuro-rehabilitation unit of an Italian hospital. J Chemother 2010; 22:212-4; PMID:20566429
28. Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, Ambretti S. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolate. J Antimicrob Chemother 2014; 69:1856-65; PMID:24648503
29. Goncalves-Pereira J, Martins A, P∫voa P. Parmacokinetics of gentamicin in critically ill patients:pilot study evaluating the first dose. Clin Microbiol Infect 2010; 16:1258-63; PMID:19832713
30. Nicolau DP. Pharmacokinetic and pharmacodynamics properties of meropenem. Clin Infect Dis 2008; 47(Suppl 1):32-40
31. Binder L, Schwörer H, Hoppe S, Streit F, Neumann S, Beckmann A, Wachter R, Oellerich M, Walson PD. Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit 2013; 35:63-70; PMID:23318279
32. Taccone FS, Lattere P, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Critical Care 2010; 14:R126; PMID:20594297
33. Drusano GL. Antimicrobial pharmacodynamics:critical interactions of ‘bug and drug’. Nat Rev Microbiol 2004; 2:289-300; PMID:15031728
34. Pankey GA, Ashcraft DS. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay. Diagn Microbiol Infect Dis 2009; 63:228-32; PMID:19150711
35. Pankey GA, Ashcraft DS. Detection of synergy using the combuination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011; 70:561-4; PMID:21767715
36. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecyline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006; 57:573-6; PMID:16431863
37. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens. J Antimicrob Chemother 2008; 61:371-4; PMID:18033780